#EYLEA
Sandoz launches a biosimilar of Eylea in the U.S.
November 19, 2026 at 8:58 AM
რეჯენერონი — კვარტალური შედეგების სრული ანალიზი ინვესტორისთვის

რეჯენერონი, როგორც ამერიკული ბიოტექნოლოგიური ინდუსტრიის მნიშვნელოვანი მოთამაშე, წარმატებით მართავს Eylea-ს პოსტ-პატენტურ გამოწვევებს და Dupixent-ის ექსპანსია ახალი ზრდის წყაროს ფუნქციას ასრულებს.

#drpkhakadze #sheniekimi
რეჯენერონი — კვარტალური შედეგების სრული ანალიზი ინვესტორისთვის
რეჯენერონი, როგორც ამერიკული ბიოტექნოლოგიური ინდუსტრიის მნიშვნელოვანი მოთამაშე, წარმატებით მართავს Eylea-ს პოსტ-პატენტურ გამოწვევებს და Dupixent-ის ექსპანსია ახალი ზრდის წყაროს ფუნქციას ასრულებს. კომპანიის საბაზრო კაპიტალიზაცია დაახლოებით ასი მილიარდი დოლარია, ხოლო აქციების ფასი შვიდასიდან რვაას დოლარის დიაპაზონში მოძრაობს.
sheniekimi.ge
November 14, 2026 at 8:10 PM
#$REGN Regeneron's profitable Dupixent franchise, strong balance sheet, and expanding drug pipeline support long-term earnings growth, although EYLEA erosion, clinical setbacks, and a richer post-rally valuation limit the margin of safety.
intickers.com/reports/regn/
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis | InTickers
Regeneron's profitable Dupixent franchise, strong balance sheet, and expanding drug pipeline support long-term…
intickers.com
November 13, 2026 at 8:00 PM
Ophthopedia Update: LUGANO trial fails to meet noninferiority endpoint in wet AMD: NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, said a phase 3 trial that assessed Duravyu for wet age-related macular degeneration “did not meet the primary endpoint of… #ophthalmology #eye #eyenews
LUGANO trial fails to meet noninferiority endpoint in wet AMD
NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, said a phase 3 trial that assessed Duravyu for wet age-related macular degeneration “did not meet the primary endpoint of noninferiority in visual acuity.” In the LUGANO trial, presented at the American Academy of Ophthalmology meeting, patients with wet AMD received either Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals) every 6 months or Eylea (aflibercept 2 mg, Regeneron) every 8 weeks. Nine patients who received Duravyu, formerly known as EYP-1901, experienced vision loss unrelated to macular drying, but when
dlvr.it
November 9, 2026 at 12:04 PM
I've been watching $REGN; Regeneron uses VelocImmune mAb tech-Dupixent (IL‑4/13), Eylea (VEGF), Libtayo (PD‑1). High‑aperture antibody lens: affinity sharpens focus, Fc tweaks exposure. Market underprices IO optionality; buy. analysi
November 4, 2026 at 1:04 PM
The Eylea HD market is set for growth in 2026, driven by rising retinal diseases, demand for long-acting anti-VEGF treatments, and advances in ophthalmic care. North America leads the market, while Asia-Pacific is expected to grow fastest.
thebusinessresearchcompany.com/report/eylea...
Eylea HD Market Size Forecast Analysis Report 2026-2030
Eylea HD market is set for strong growth, driven by rising eye disorder prevalence and personalized medicine adoption. Key players: Regeneron Pharmaceuticals Inc, Bayer AG.
thebusinessresearchcompany.com
November 2, 2026 at 12:57 PM
#Nubeqa

🇩🇪 #$BAYN Bayer Q3 sales €10,053m, +1.9% without currency and deals. Nubeqa €998m tops Xarelto plus Eylea. Net loss €672m after write-downs. Net debt fell on Apollo's €3.0bn.

2026 guide up: EBITDA €9.8-10.3bn, free cash flow still −€1.5 to −€0.5bn.

midgardfinance.com/companies/BAYN.DE/
November 3, 2026 at 7:55 AM
#Nubeqa

🇩🇪 #$BAYN Bayer Q3 sales €10,053m, +1.9% without currency and deals. Nubeqa €998m tops Xarelto plus Eylea. Net loss €672m after write-downs. Net debt fell on Apollo's €3.0bn.

2026 guide up: EBITDA €9.8-10.3bn, free cash flow still −€1.5 to −€0.5bn.

midgardfinance.com/companies/BAYN.DE/
November 3, 2026 at 7:55 AM
Ophthopedia Update: Zenkuda for wet AMD ‘impressive and encouraging’ at 1 year: NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, of Retina Vitreous Associates of Florida, highlights data from the phase 3 DAYBREAK trial on the use of Zenkuda for the… #ophthalmology #eye #eyenews
Zenkuda for wet AMD ‘impressive and encouraging’ at 1 year
NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, of Retina Vitreous Associates of Florida, highlights data from the phase 3 DAYBREAK trial on the use of Zenkuda for the treatment of wet age-related macular degeneration. In the DAYBREAK clinical trial, presented at the American Academy of Ophthalmology meeting, researchers assessed Zenkuda (tarcocimab tedromer, Kodiak Sciences) and KSI-501 (tabirafusp alfa tedromer, Kodiak Sciences) vs. Eylea (aflibercept, Regeneron) in patients with wet AMD. Eichenbaum said 54% of patients who received Zenkuda went out as far as 6 months without
dlvr.it
November 2, 2026 at 2:11 PM
Regeneron's Q3 Revenue Jumps 36% on Dupixent, Eylea HD Growth #MarketUpdates Follow Us for more
Regeneron's Q3 Revenue Jumps 36% on Dupixent, Eylea HD
Regeneron's third-quarter revenue climbed 36% to $5.12 billion, beating analyst expectations, driven by record sales of Dupixent, Eylea HD and Libtayo.
quantli.com
October 30, 2026 at 10:02 PM
#Dupixent #EYLEA

🇺🇸 #$REGN Q3 revenue $5.1bn, +36%. Regeneron's share of Dupixent and Kevzara profits, now half of revenue, rose 77% on Dupixent sales +35%, helped by repayments to Sanofi ending. Global: EYLEA HD +63%, EYLEA −49%. GAAP EPS +35%, non-GAAP +70%.

midgardfinance.com/companies/REGN/
October 30, 2026 at 12:40 PM
#$REGN stock climbed 7% premarket after beating Q3 forecasts. Revenue grew 36% and non-GAAP EPS rose 70% on record Dupixent and EYLEA HD sales. notreload.xyz/xy/strong-du...
Strong Dupixent Sales Power Regeneron Earnings Beat
Revenue grew 36% and non-GAAP EPS rose 70% on record Dupixent and EYLEA HD sales.
notreload.xyz
October 30, 2026 at 11:28 AM
#$REGN Q3'26 earnings — massive beat across the board:

- Revenue $5.1B vs $4.54B est; +36% YoY
- Adj. EPS $20.07 vs $16.24 est; +70% YoY
- Dupixent global sales $6.5B (+35%), EYLEA HD $699M (+62%), Libtayo $550M (+51%) — all record quarters
October 30, 2026 at 10:35 AM
Regeneron Pharmaceuticals Inc. and Amgen Inc. asked a West Virginia federal court to dismiss infringement claims and counterclaims over two patents covering proposed Eylea biosimilars.
Regeneron, Amgen Further Narrow Lawsuit Over Eylea Biosimilars
Regeneron Pharmaceuticals Inc. and Amgen Inc. asked a West Virginia federal court to dismiss infringement claims and counterclaims over two patents covering proposed Eylea biosimilars.
bit.ly
October 28, 2026 at 6:00 AM
Ophthopedia Update: Real-world wet AMD outcomes improved with aflibercept 8 mg: VIENNA — A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased retinal drying and no new safety signals.
SPECTRUM is an… #ophthalmology #eye #eyenews
Real-world wet AMD outcomes improved with aflibercept 8 mg
VIENNA — A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased retinal drying and no new safety signals. SPECTRUM is an ongoing, global, phase 4 prospective observational study evaluating the real-world effectiveness and safety of Eylea HD (aflibercept 8 mg, Regeneron/Bayer) in patients with age-related macular degeneration or diabetic macular edema. At the Euretina congress, Marion R. Munk, MD, PhD, presented new outcomes for the neovascular AMD subgroup. “The pretreated neovascular AMD group included 1,100 patients who had
dlvr.it
October 27, 2026 at 7:52 PM
Ophthopedia Update: Real-world wet AMD outcomes improved with aflibercept 8 mg: VIENNA — A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased retinal drying and no new safety signals.
SPECTRUM is an ongoing, global, phase 4…
Real-world wet AMD outcomes improved with aflibercept 8 mg
VIENNA — A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased retinal drying and no new safety signals. SPECTRUM is an ongoing, global, phase 4 prospective observational study evaluating the real-world effectiveness and safety of Eylea HD (aflibercept 8 mg, Regeneron/Bayer) in patients with age-related macular degeneration or diabetic macular edema. At the Euretina congress, Marion R. Munk, MD, PhD, presented new outcomes for the neovascular AMD subgroup. “The pretreated neovascular AMD group included 1,100 patients who had
dlvr.it
October 27, 2026 at 7:44 PM
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to...
www.jdsupra.com
October 22, 2026 at 6:15 PM
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to...
www.jdsupra.com
October 22, 2026 at 6:15 PM
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
Alvotech and Advanz Pharma Announce Submission for Proposed Eylea 8 mg Biosimilar
On October 14, 2026, Alvotech and Advanz Pharma announced the submission of a European regulatory application for AVT29, a proposed biosimilar to...
www.jdsupra.com
October 22, 2026 at 6:15 PM
#ALVO Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

https://www.stocktitan.net/news/ALVO/alvotech-and-advanz-pharma-announce-first-known-regulatory-aj0gfaij65kh.html?utm_source=stocktitan-bluesky&utm_medium=social
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Alvotech (ALVO) and Advanz Pharma announced a European regulatory submission for AVT29, a proposed biosimilar to Eylea 8 mg. The application was submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli, Alvotech’s biosimilar to Eylea 2 mg. Mynzepli received European Commission approval in August 2025 in vial and prefilled syringe presentations for various retinal diseases.Alvotech is responsible for development and commercial supply of AVT06 and AVT29, while Advanz Pharma handles registration and commercialization in Europe. The approved European information for Eylea 8 mg allows 16-week treatment intervals for certain patients, compared with the standard eight-week maintenance interval for the original 2 mg formulation. AVT29 remains investigational; regulatory authorities have not yet established its biosimilarity.
www.stocktitan.net
October 14, 2026 at 8:30 AM
My mom gets Eylea injections..it's crazy the cost
October 12, 2026 at 3:53 AM
Ophthopedia Update: Comparative Clinical and Therapeutic Landscape of Aflibercept Biosimilars (YESAFILI), High-Dose Aflibercept 8 mg (EYLEA HD), and Faricimab (VABYSMO): A Structured Narrative Review #Ophthomology #Eye #Ophthotwitter
Comparative Clinical and Therapeutic Landscape of Aflibercept Biosimil | OPTH | Dove Medical Press
Reference aflibercept 2 mg (EYLEA; Regeneron/Bayer) remains a foundational therapy for neovascular age-related macular degeneration
dlvr.it
October 7, 2026 at 11:27 AM
Ophthopedia Update: Study shows long-term efficacy, safety of aflibercept 0.4 mg in ROP: VIENNA — Aflibercept 0.4 mg intravitreal injection in preterm and low birthweight infants with acute-phase retinopathy of prematurity was effective and well tolerated over 5 years… #ophthalmology #eye #eyenews
Study shows long-term efficacy, safety of aflibercept 0.4 mg in ROP
VIENNA — Aflibercept 0.4 mg intravitreal injection in preterm and low birthweight infants with acute-phase retinopathy of prematurity was effective and well tolerated over 5 years of follow-up in a study presented at the Euretina congress. Based on the original FIREFLEYE study, FIREFLEYE next was the first prospective controlled phase 3b study evaluating the long-term efficacy and safety of Eylea (aflibercept 0.4 mg; Regeneron, Bayer) vs. laser photocoagulation. “We followed all treated infants for up to 5 years and had a very good retention rate, with 98 out of 113 patients at the end of this
dlvr.it
October 5, 2026 at 7:35 PM